Status:

TERMINATED

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Lead Sponsor:

Clovis Oncology, Inc.

Conditions:

Breast Cancer

Metastatic Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with ...

Detailed Description

Lucitanib is a selective, orally available tyrosine kinase inhibitor targeting FGFR1-3, VEGFR1-3, and PDGFRα and β, with activity in relevant cell lines and animal models. The first in human trial of...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed metastatic breast cancer relapsed or refractory to approved standard available treatment
  • Prior treatment with standard first line therapy in the metastatic setting
  • Availability of tumor tissue sufficient for confirmatory testing of FGFR1 and 11q amplification status
  • Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)
  • Estimated life expectancy \>6 months

Exclusion

  • Current or recent treatment with biologic anticancer therapies
  • Ongoing AEs from prior anticancer therapies
  • Active central nervous system (CNS) metastases
  • Clinically significant or uncontrolled hypertension or cardiac disease
  • Females who are pregnant or breastfeeding

Key Trial Info

Start Date :

September 9 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 18 2017

Estimated Enrollment :

178 Patients enrolled

Trial Details

Trial ID

NCT02202746

Start Date

September 9 2014

End Date

January 18 2017

Last Update

June 23 2020

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Arizona Oncology Associates

Sedona, Arizona, United States, 86336

2

Comprehensive Blood and Cancer Center

Bakersfield, California, United States, 93309

3

Saint Jude Heritage Medical Center

Fullerton, California, United States, 92835

4

Moores UCSD Cancer Center

La Jolla, California, United States, 92093